Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration by Stein, Mark N, Malhotra, Jyoti, Tarapore, Rohinton S, Malhotra, Usha, Silk, Ann W, Chan, Nancy, Rodriguez, Lorna, Aisner, Joseph, Aiken, Robert D, Mayer, Tina, Haffty, Bruce G, Newman, Jenna H, Aspromonte, Salvatore M, Bommareddy, Praveen K, Estupinian, Ricardo, Chesson, Charles B, Sadimin, Evita T, Li, Shengguo, Medina, Daniel J, Saunders, Tracie, Frankel, Melissa, Kareddula, Aparna, Damare, Sherrie, Wesolowsky, Elayne, Gabel, Christian, El-Deiry, Wafik S, Prabhu, Varun V, Allen, Joshua E, Stogniew, Martin, Oster, Wolfgang, Bertino, Joseph R, Libutti, Steven K, Mehnert, Janice M, Zloza, Andrew

Get full text